Synopsis
Synopsis
0
JDMF
0
VMF
0
Australia
Annual Reports
NA
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. Antaxone
2. Celupan
3. En 1639a
4. En-1639a
5. En1639a
6. Nalorex
7. Naltrexone
8. Nemexin
9. Revia
10. Trexan
1. Naltrexone Hcl
2. 16676-29-2
3. Trexan
4. Depade
5. Antaxone
6. Revia
7. Naltrexone (hydrochloride)
8. En-1639a
9. Nih 8503
10. Celupan
11. Nemexin
12. N-cyclopropylmethyl-noroxymorphone Hydrochloride
13. Mls000069607
14. Naltrexone Hydrochloride [usp]
15. Z6375yw9sf
16. Vivitrex
17. 17-(cyclopropylmethyl)-4,5-alpha-epoxy-3,14-dihydroxy-morphinan-6-one Hydrochloride
18. Nalorex
19. Smr000058767
20. En-1639a (as Hydrochloride)
21. En 1639a
22. (4r,4as,7ar,12bs)-3-(cyclopropylmethyl)-4a,9-dihydroxy-2,4,5,6,7a,13-hexahydro-1h-4,12-methanobenzofuro[3,2-e]isoquinolin-7-one;hydrochloride
23. Naltrexone Hydrochloride (usp)
24. (4r,4as,7ar,12bs)-3-(cyclopropylmethyl)-4a,9-dihydroxy-2,3,4,4a,5,6-hexahydro-1h-4,12-methanobenzofuro[3,2-e]isoquinolin-7(7ah)-one Hydrochloride
25. Morphinan-6-one, 17-(cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxy-, Hydrochloride (1:1), (5alpha)-
26. Ccris 1168
27. Einecs 240-723-0
28. Unii-z6375yw9sf
29. Naltrel
30. Naltrexone.hcl
31. Naltrexone Depot
32. Prestwick_348
33. Mfcd00069324
34. (5alpha)-17-(cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxymorphinan-6-one Hydrochloride
35. Revia (tn)
36. Xr-ntx
37. (4r,4as,7ar,12bs)-3-(cyclopropylmethyl)-4a,9-dihydroxy-2,4,5,6,7a,13-hexahydro-1h-4,12-methanobenzofuro[3,2-e]isoquinoline-7-one;hydrochloride
38. Opera_id_1828
39. Naltrexone Monohydrochloride
40. Morphinan-6-one, 17-(cyclopropylmethyl)-4,5-alpha-epoxy-3,14-dihydroxy-, Hydrochloride
41. Morphinan-6-one, 17-(cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxy-, Hydrochloride, (5-alpha)-
42. Schembl37713
43. Mls001076516
44. Mls002153483
45. Mls002695940
46. Cyto-205
47. Chembl1201149
48. Dtxsid50937236
49. Pti-901
50. Chebi:134687
51. Bcp08343
52. Naltrexone Hydrochloride [mi]
53. S2103
54. Vp-004
55. Akos015994597
56. Ccg-268383
57. Cs-0763
58. Hs-0003
59. Nc00693
60. 17-cyclopropylmethyl)-4,5alpha-epoxy-3,14-dihydroxymorphinan-6-one Hydrochloride
61. Morphinan-6-one, 17-(cyclopropylmethyl)-4,5-alpha-oxy-3,14-dihydoxy-, Hydrochloride
62. Morphinan-6-one, 17-(cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxy-, Hydrochloride, (5alpha)-
63. Naltrexone Hydrochloride [mart.]
64. Naltrexone Hydrochloride [vandf]
65. Naltrexone Hydrochloride [who-dd]
66. Bn164635
67. Hy-76710
68. Morphinan-6-one, 17-(cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxy-, Hydrochloride, (5.alpha.)-
69. N1176
70. Naltrexone Hydrochloride [green Book]
71. Sw196619-3
72. Naltrexone Hydrochloride [orange Book]
73. D02095
74. Embeda Component Naltrexone Hydrochloride
75. H10489
76. Naltrexone Hydrochloride [ep Monograph]
77. Naltrexone Hydrochloride [usp Monograph]
78. Troxyca Component Naltrexone Hydrochloride
79. 676n292
80. Contrave Component Naltrexone Hydrochloride
81. Naltrexone Hydrochloride Component Of Embeda
82. Naltrexone Hydrochloride Component Of Troxyca
83. Naltrexone Hydrochloride Component Of Contrave
84. Q27096434
85. Z1558290144
86. Naltrexone Hydrochloride 1.0 Mg/ml In Methanol (as Free Base)
87. Naltrexone Hydrochloride, European Pharmacopoeia (ep) Reference Standard
88. (5a)-17-(cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxy-morphinan-6-one Hydrochloride
89. 17-(cyclopropylmethyl)-3,14-dihydroxy-4,5alpha-epoxymorphinan-6-one Hydrochloride
90. 17-cyclopropylmethyl)-4,5.alpha.-epoxy-3,14-dihydroxymorphinan-6-one Hydrochloride
91. (1s,5r,13r,17s)-4-(cyclopropylmethyl)-10,17-dihydroxy-12-oxa-4-azapentacyclo[9.6.1.0^{1,13}.0^{5,17}.0^{7,18}]octadeca-7(18),8,10-trien-14-one Hydrochloride
92. (4r,4as,7ar,12bs)-3-(cyclopropylmethyl)-4a,9-dihydroxy-2,4,5,6,7a,13-hexahydro-1h-4,12-methanobenzofuro[3,2-e]isoquinolin-7-one;hydron;chloride
93. (5alpha,17r)-17-(cyclopropylmethyl)-3,14-dihydroxy-6-oxo-4,5-epoxymorphinan-17-ium Chloride
94. Morphinan-6-one, 17-(cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxy-, (5.alpha.)-, Hydrochloride (1:1)
Molecular Weight | 377.9 g/mol |
---|---|
Molecular Formula | C20H24ClNO4 |
Hydrogen Bond Donor Count | 3 |
Hydrogen Bond Acceptor Count | 5 |
Rotatable Bond Count | 2 |
Exact Mass | 377.1393859 g/mol |
Monoisotopic Mass | 377.1393859 g/mol |
Topological Polar Surface Area | 70 Ų |
Heavy Atom Count | 26 |
Formal Charge | 0 |
Complexity | 621 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 4 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 2 |
1 of 6 | |
---|---|
Drug Name | Naltrexone hydrochloride |
PubMed Health | Naltrexone |
Drug Classes | Ethanol Dependency, Opioid Dependency, Toxicology-Antidote Agent |
Drug Label | Naltrexone hydrochloride, an opioid antagonist, is a synthetic congener of oxymorphone with no opioid agonist properties. Naltrexone differs in structure from oxymorphone in that the methyl group on the nitrogen atom is replaced by a cyclopropylmethy... |
Active Ingredient | Naltrexone hydrochloride |
Dosage Form | Tablet |
Route | Oral |
Strength | 25mg; 100mg; 50mg |
Market Status | Prescription |
Company | Accord Hlthcare; Mallinckrodt; Sun Pharma Global; Elite Labs; Barr |
2 of 6 | |
---|---|
Drug Name | Revia |
PubMed Health | Naltrexone |
Drug Classes | Ethanol Dependency, Opioid Dependency, Toxicology-Antidote Agent |
Drug Label | REVIA (naltrexone hydrochloride tablets USP), an opioid antagonist, is a synthetic congener of oxymorphone with no opioid agonist properties. Naltrexone differs in structure from oxymorphone in that the methyl group on the nitrogen atom is replaced... |
Active Ingredient | Naltrexone hydrochloride |
Dosage Form | Tablet |
Route | Oral |
Strength | 50mg |
Market Status | Prescription |
Company | Teva Womens |
3 of 6 | |
---|---|
Drug Name | Vivitrol |
Active Ingredient | Naltrexone |
Dosage Form | For suspension, extended release |
Route | Intramuscular |
Strength | 380mg/vial |
Market Status | Prescription |
Company | Alkermes |
4 of 6 | |
---|---|
Drug Name | Naltrexone hydrochloride |
PubMed Health | Naltrexone |
Drug Classes | Ethanol Dependency, Opioid Dependency, Toxicology-Antidote Agent |
Drug Label | Naltrexone hydrochloride, an opioid antagonist, is a synthetic congener of oxymorphone with no opioid agonist properties. Naltrexone differs in structure from oxymorphone in that the methyl group on the nitrogen atom is replaced by a cyclopropylmethy... |
Active Ingredient | Naltrexone hydrochloride |
Dosage Form | Tablet |
Route | Oral |
Strength | 25mg; 100mg; 50mg |
Market Status | Prescription |
Company | Accord Hlthcare; Mallinckrodt; Sun Pharma Global; Elite Labs; Barr |
5 of 6 | |
---|---|
Drug Name | Revia |
PubMed Health | Naltrexone |
Drug Classes | Ethanol Dependency, Opioid Dependency, Toxicology-Antidote Agent |
Drug Label | REVIA (naltrexone hydrochloride tablets USP), an opioid antagonist, is a synthetic congener of oxymorphone with no opioid agonist properties. Naltrexone differs in structure from oxymorphone in that the methyl group on the nitrogen atom is replaced... |
Active Ingredient | Naltrexone hydrochloride |
Dosage Form | Tablet |
Route | Oral |
Strength | 50mg |
Market Status | Prescription |
Company | Teva Womens |
6 of 6 | |
---|---|
Drug Name | Vivitrol |
Active Ingredient | Naltrexone |
Dosage Form | For suspension, extended release |
Route | Intramuscular |
Strength | 380mg/vial |
Market Status | Prescription |
Company | Alkermes |
Alcohol Deterrents
Substances interfering with the metabolism of ethyl alcohol, causing unpleasant side effects thought to discourage the drinking of alcoholic beverages. Alcohol deterrents are used in the treatment of alcoholism. (See all compounds classified as Alcohol Deterrents.)
Narcotic Antagonists
Agents inhibiting the effect of narcotics on the central nervous system. (See all compounds classified as Narcotic Antagonists.)
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
DRUG PRODUCT COMPOSITIONS
Related Excipient Companies
Excipients by Applications
Global Sales Information
Market Place
Patents & EXCLUSIVITIES
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
25
PharmaCompass offers a list of Naltrexone Hydrochloride API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Naltrexone Hydrochloride manufacturer or Naltrexone Hydrochloride supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Naltrexone Hydrochloride manufacturer or Naltrexone Hydrochloride supplier.
PharmaCompass also assists you with knowing the Naltrexone Hydrochloride API Price utilized in the formulation of products. Naltrexone Hydrochloride API Price is not always fixed or binding as the Naltrexone Hydrochloride Price is obtained through a variety of data sources. The Naltrexone Hydrochloride Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A CONTRAVE-1 manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of CONTRAVE-1, including repackagers and relabelers. The FDA regulates CONTRAVE-1 manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. CONTRAVE-1 API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of CONTRAVE-1 manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A CONTRAVE-1 supplier is an individual or a company that provides CONTRAVE-1 active pharmaceutical ingredient (API) or CONTRAVE-1 finished formulations upon request. The CONTRAVE-1 suppliers may include CONTRAVE-1 API manufacturers, exporters, distributors and traders.
click here to find a list of CONTRAVE-1 suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A CONTRAVE-1 DMF (Drug Master File) is a document detailing the whole manufacturing process of CONTRAVE-1 active pharmaceutical ingredient (API) in detail. Different forms of CONTRAVE-1 DMFs exist exist since differing nations have different regulations, such as CONTRAVE-1 USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A CONTRAVE-1 DMF submitted to regulatory agencies in the US is known as a USDMF. CONTRAVE-1 USDMF includes data on CONTRAVE-1's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The CONTRAVE-1 USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of CONTRAVE-1 suppliers with USDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a CONTRAVE-1 Drug Master File in Korea (CONTRAVE-1 KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of CONTRAVE-1. The MFDS reviews the CONTRAVE-1 KDMF as part of the drug registration process and uses the information provided in the CONTRAVE-1 KDMF to evaluate the safety and efficacy of the drug.
After submitting a CONTRAVE-1 KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their CONTRAVE-1 API can apply through the Korea Drug Master File (KDMF).
click here to find a list of CONTRAVE-1 suppliers with KDMF on PharmaCompass.
A CONTRAVE-1 CEP of the European Pharmacopoeia monograph is often referred to as a CONTRAVE-1 Certificate of Suitability (COS). The purpose of a CONTRAVE-1 CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of CONTRAVE-1 EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of CONTRAVE-1 to their clients by showing that a CONTRAVE-1 CEP has been issued for it. The manufacturer submits a CONTRAVE-1 CEP (COS) as part of the market authorization procedure, and it takes on the role of a CONTRAVE-1 CEP holder for the record. Additionally, the data presented in the CONTRAVE-1 CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the CONTRAVE-1 DMF.
A CONTRAVE-1 CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. CONTRAVE-1 CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of CONTRAVE-1 suppliers with CEP (COS) on PharmaCompass.
A CONTRAVE-1 written confirmation (CONTRAVE-1 WC) is an official document issued by a regulatory agency to a CONTRAVE-1 manufacturer, verifying that the manufacturing facility of a CONTRAVE-1 active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting CONTRAVE-1 APIs or CONTRAVE-1 finished pharmaceutical products to another nation, regulatory agencies frequently require a CONTRAVE-1 WC (written confirmation) as part of the regulatory process.
click here to find a list of CONTRAVE-1 suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing CONTRAVE-1 as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for CONTRAVE-1 API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture CONTRAVE-1 as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain CONTRAVE-1 and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a CONTRAVE-1 NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of CONTRAVE-1 suppliers with NDC on PharmaCompass.
CONTRAVE-1 Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of CONTRAVE-1 GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right CONTRAVE-1 GMP manufacturer or CONTRAVE-1 GMP API supplier for your needs.
A CONTRAVE-1 CoA (Certificate of Analysis) is a formal document that attests to CONTRAVE-1's compliance with CONTRAVE-1 specifications and serves as a tool for batch-level quality control.
CONTRAVE-1 CoA mostly includes findings from lab analyses of a specific batch. For each CONTRAVE-1 CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
CONTRAVE-1 may be tested according to a variety of international standards, such as European Pharmacopoeia (CONTRAVE-1 EP), CONTRAVE-1 JP (Japanese Pharmacopeia) and the US Pharmacopoeia (CONTRAVE-1 USP).